PMID- 22166938
OWN - NLM
STAT- MEDLINE
DCOM- 20120608
LR  - 20230203
IS  - 1935-3456 (Electronic)
IS  - 1933-0219 (Print)
IS  - 1933-0219 (Linking)
VI  - 5
IP  - 2
DP  - 2012 Mar
TI  - Directed antigen targeting in vivo identifies a role for CD103+ dendritic cells 
      in both tolerogenic and immunogenic T-cell responses.
PG  - 150-60
LID - 10.1038/mi.2011.61 [doi]
AB  - The alphaE integrin chain CD103 identifies a subset of migratory dendritic cells 
      (DCs) in the gut, lung, and skin. To gain further understanding of the function 
      of CD103(+) DCs in regulating adaptive immunity in vivo, we coupled ovalbumin 
      (OVA) to the CD103 antibody M290 (M290.OVA). Intraperitoneal injection of 
      M290.OVA induced OVA-specific CD8(+) and CD4(+) T-cell proliferation in lymph 
      nodes (LNs) of wild-type but not CD103(-/-) mice, or in mice depleted of CD11c(+) 
      cells. In the absence of maturation stimuli, systemic antigen targeting to 
      CD103(+) DCs led to tolerance of CD8(+) T cells, whereas coadministration of 
      adjuvant induced cytotoxic T-lymphocyte (CTL) immunity and antibody production. 
      Mucosal intratracheal application of M290.OVA also induced T-cell proliferation 
      in mediastinal LNs, yet the functional outcome was tolerance that inhibited 
      subsequent development of allergic airway inflammation and immunoglobulin E (IgE) 
      responses to inhaled OVA. These findings identify antigen targeting to CD103(+) 
      DCs as a potential strategy to regulate immune responses in nonlymphoid mucosal 
      tissues.
FAU - Semmrich, M
AU  - Semmrich M
AD  - Immunology Section, Lund University, Lund, Sweden.
FAU - Plantinga, M
AU  - Plantinga M
FAU - Svensson-Frej, M
AU  - Svensson-Frej M
FAU - Uronen-Hansson, H
AU  - Uronen-Hansson H
FAU - Gustafsson, T
AU  - Gustafsson T
FAU - Mowat, A M
AU  - Mowat AM
FAU - Yrlid, U
AU  - Yrlid U
FAU - Lambrecht, B N
AU  - Lambrecht BN
FAU - Agace, W W
AU  - Agace WW
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111214
PL  - United States
TA  - Mucosal Immunol
JT  - Mucosal immunology
JID - 101299742
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens)
RN  - 0 (Antigens, CD)
RN  - 0 (Integrin alpha Chains)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (alpha E integrins)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/genetics/immunology/metabolism
MH  - Antibody Formation
MH  - Antigens/genetics/immunology/metabolism
MH  - Antigens, CD/genetics/*metabolism
MH  - CD4-Positive T-Lymphocytes/immunology/*metabolism/pathology
MH  - CD8-Positive T-Lymphocytes/immunology/*metabolism/pathology
MH  - Cell Proliferation
MH  - Cytotoxicity, Immunologic
MH  - Dendritic Cells/immunology/*metabolism/pathology
MH  - Drug Administration Routes
MH  - Humans
MH  - Immune Tolerance
MH  - Immunization
MH  - Immunomodulation
MH  - Integrin alpha Chains/genetics/*metabolism
MH  - Mice
MH  - Mice, Knockout
MH  - Ovalbumin/genetics/immunology/metabolism
MH  - Protein Engineering
MH  - Recombinant Fusion Proteins/genetics
PMC - PMC3282433
EDAT- 2011/12/15 06:00
MHDA- 2012/06/09 06:00
CRDT- 2011/12/15 06:00
PHST- 2011/12/15 06:00 [entrez]
PHST- 2011/12/15 06:00 [pubmed]
PHST- 2012/06/09 06:00 [medline]
AID - S1933-0219(22)01292-2 [pii]
AID - 10.1038/mi.2011.61 [doi]
PST - ppublish
SO  - Mucosal Immunol. 2012 Mar;5(2):150-60. doi: 10.1038/mi.2011.61. Epub 2011 Dec 14.